secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2023-06-06T23:59:59+00:00
Accession:  0001645113-23-000041
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phase 3 LUNAR trial meets primary endpoint: TTFields + SOC improves OS in NSCLC
-------------------------------------------------------------------------------

- Median OS 13.2 months for TTFields+SOC vs 9.9 months for SOC alone (HR 0.74, p=0.035).
- In ICI subgroup, median OS 18.5 vs 10.8 months (HR 0.63, p=0.03); in docetaxel 11.1 vs 8.7 months (HR 0.81, p=0.28).
- No added systemic toxicities; most common device effect was grade 1-2 dermatitis (43%).
- Company plans to submit for regulatory approval; first-line NSCLC studies underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000041/0001645113-23-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511323000041/nvcr-20230606.htm
  HTML page:      https://secwatch.observer/filing/0001645113-23-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer